ArticleInternational journal of molecular sciences2026
Cognitive and Neurochemical Effects of Brivaracetam Co-Administered with Ethanol: A Preclinical Study.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ethanol affects the central nervous system, with frequent use leading to memory impairment. This study aims to determine the effects of brivaracetam on ethanol-induced memory impairment and alterations in selected neurotransmitter levels, trace elements in the brain and serum oxidative stress parameters in rats. Brivaracetam was administered for three weeks (6 mg/kg b.w.) before behavioral tests. Ethanol was given as a forced model (5 g/kg b.w.). Spatial memory was evaluated with the Morris water maze test and recognition memory with the novel object recognition test. GABA and glutamate concentrations were evaluated in the cerebellum, hippocampus, and cerebral cortex, while superoxide dismutase (SOD) and catalase (CAT) activities and malondialdehyde (MDA) levels were measured in blood serum. The levels of copper, manganese, zinc, iron, and magnesium in the brain were also determined. Brivaracetam was found to negatively affect spatial and retrieval memory when administered with ethanol and during withdrawal; however, the drug improved ethanol-induced short-term recognition memory impairment. Furthermore, brivaracetam increased CAT activity, while MDA was decreased and SOD increased in all drug-treated animals. Brivaracetam may counteract ethanol-induced manganese brain concentration, but increases iron, magnesium, and copper concentrations. Hence, brivaracetam use induces various effects on the central nervous system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.